FoxHollow/Merck R&D Deal: The Value of Plaque
Executive Summary
An unusual pharmacogenomics alliance between a device company a major pharmaceutical company opens up new markets for both partners.
You may also be interested in...
Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.